Viking Therapeutics' Oral Pill Could Challenge Eli Lilly and Novo Nordisk in Weight Loss Market

In a weight loss drug market dominated by Eli Lilly (LLY) and Novo Nordisk, Viking Therapeutics is positioning itself as a potential disruptor. According to a report from Motley Fool, Viking is developing an oral pill called VK2735 that has shown promising early clinical results.

Details

VK2735 is a dual agonist of GLP-1 and GIP receptors, the same mechanism used by Eli Lilly's Mounjaro. However, VK2735 is administered orally, which could offer a significant convenience advantage over injectable drugs. In a Phase 1 trial, the drug demonstrated notable weight loss with manageable side effects.

Context

The obesity drug market is rapidly expanding, with estimates exceeding $100 billion by 2030. Eli Lilly and Novo Nordisk currently dominate, but smaller players like Viking, Amgen, and Pfizer are vying for a share. Viking is still in early stages compared to its competitors, but its early data is compelling.

What It Means for Investors

For Eli Lilly investors, Viking does not pose an immediate threat but represents a potential long-term risk. Viking needs additional funding and must pass larger clinical trials, meaning years before market entry. Investors interested in the obesity space may add Viking to their watchlist, acknowledging the high risk associated with early-stage biotech investments.